A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Recruiting · NCT07776743 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 2 | 2026-08-20 | NCT07776743 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Lupeng Pharmaceutical Company LTD. | 12 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tiantan Hospital, Capital Medical University | Beijing | China | 9 |